SLC5A2 and type 2 diabetes mellitus: Among these five trials, four trials recruited patients with T2DM/HF with or without HF/T2DM; thus, the data from their subgroup analyses comparing SGLT-2 inhibitors with placebo in patients with both T2DM and HF were pooled into the meta-analysis.